MedTrace Logo

CMV Glycoprotein B (gB) Vaccine Long Term Antibody Response

NCT01883206 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2017-10-27

No results posted yet for this study

Summary

The purpose of this study is to see how well the antibody levels found months to years after patients entered a previous randomised placebo-controlled trial of a glycoprotein B vaccine against cytomegalovirus have persisted and to have the previous samples retested using different methods which have been further developed in different laboratories.

Also, to prepare monoclonal antibodies from the B lymphocytes of these patients and define their strength. If potent antibodies are identified, the investigators would like to consider developing them further to see if they can protect future transplant patients against cytomegalovirus.

Conditions

  • Viraemia

Sponsors & Collaborators

  • University College, London

    lead OTHER

Principal Investigators

  • Paul D Griffiths · UCL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01883206 on ClinicalTrials.gov